Free Trial
LON:OBD

Oxford BioDynamics Interim Earnings Results & Report

Oxford BioDynamics logo
GBX 0.11 -0.01 (-8.33%)
As of 11:20 AM Eastern

Oxford BioDynamics reported Interim earnings on June 30, 2026. The company reported EPS of -GBX 0.10.

Earnings Announcement Details

Quarter
Interim
Report Date
Time
Before Market Opens

Oxford BioDynamics EPS Results

Actual EPS
-GBX 0.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Oxford BioDynamics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Oxford BioDynamics Interim Earnings FAQ

Oxford BioDynamics (LON:OBD) reported earnings of -GBX 0.10 per share for Interim. The report was announced on Tuesday, June 30, 2026.

Oxford BioDynamics Earnings Headlines

Delayed Settlement Resolved
Your Social Security check is scheduled for a 22% cut
The U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.tc pixel
See More Oxford BioDynamics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oxford BioDynamics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oxford BioDynamics and other key companies, straight to your email.

About Oxford BioDynamics

Oxford BioDynamics (LON:OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022. In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit. The Company has developed a proprietary 3D genomic biomarker platform, EpiSwitch®, which can build molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications. Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma. The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 10,000 samples in more than 30 human diseases. OBD is headquartered in Oxford, UK. It also has a commercial office in Gaithersburg, MD, USA and a reference laboratory in Penang, Malaysia. For more information, please visit the Company's website, www.oxfordbiodynamics.com, or follow on Twitter or LinkedIn. About EpiSwitch® The 3D configuration of the genome plays a crucial role in gene regulation. By mapping this architecture and identifying abnormal configurations, EpiSwitch® can be used to diagnose patients or determine how individuals might respond to a disease or treatment. Built on over 10 years of research, EpiSwitch® is Oxford Biodynamics' award-winning, proprietary platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarkers. The technology is fully developed, based on testing of over 10,000 samples in 30 disease areas, and reduced to practice. In addition to stratifying patients with respect to anticipated clinical outcome, EpiSwitch® data offer insights into systems biology and the physiological manifestation of disease that are beyond the scope of other molecular modalities. The technology has performed well in academic medical research settings and has been validated through its integration in biomarker discovery and clinical development with big pharma.

View Oxford BioDynamics Profile